AFATINIB DIMALEATE | N201292 | BOEHRINGER INGELHEIM
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. et al v. TEVA PHARMACEUTICALS USA, INC. et al 2 patentsANDA 210768afatinib | D.N.J. | 2017-11-10 | Terminated 2018-05-02 | — |
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. et al v. SUN PHARMACEUTICAL INDUSTRIES LTD. et al 1 patentANDA 210814afatinib | D.N.J. | 2017-10-20 | Terminated 2018-05-02 | — |
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. et al v. SANDOZ, INC. 4 patentsANDA 210703afatinib | D.N.J. | 2017-10-20 | Terminated 2018-05-02 | — |
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. et al v. HETERO USA INC. et al 1 patentANDA 210750afatinib | D.N.J. | 2017-10-05 | Terminated 2018-05-02 | — |
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. et al v. AUROBINDO PHARMA USA INC. et al 2 patentsANDA 210770afatinib | D.N.J. | 2017-10-04 | Terminated 2020-11-12 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).